A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | MicrobiomeTrials
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-11-25Est. Completion: 2029-05
Enrollment target: 180 participants
Locations
Yale University School of Medicine /ID# 278181, New Haven, Connecticut, United States
Ocala Oncology Center /ID# 278269, Ocala, Florida, United States
Moffitt Cancer Center /ID# 277573, Tampa, Florida, United States
Fort Wayne Medical Oncology And Hematology /ID# 277336, Fort Wayne, Indiana, United States
Baptist Health Lexington /ID# 277729, Lexington, Kentucky, United States
Dana-Farber Cancer Institute /ID# 277732, Boston, Massachusetts, United States
University Hospitals Cleveland Medical Center /ID# 277556, Cleveland, Ohio, United States
The University of Texas MD Anderson Cancer Center /ID# 277929, Houston, Texas, United States
Virginia Cancer Specialists - Fairfax /ID# 278298, Fairfax, Virginia, United States
Grand Hopital de Charleroi - Les Viviers /ID# 276897, Charleroi, Hainaut, Belgium
Groupe Sante CHC - Clinique du MontLegia /ID# 276783, Liège, Liege, Belgium